294 related articles for article (PubMed ID: 21392074)
1. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Keating GM; Santoro A
Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Gomo C; Coriat R; Faivre L; Mir O; Ropert S; Billemont B; Dauphin A; Tod M; Goldwasser F; Blanchet B
Invest New Drugs; 2011 Dec; 29(6):1511-4. PubMed ID: 20706860
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
Lathia C; Lettieri J; Cihon F; Gallentine M; Radtke M; Sundaresan P
Cancer Chemother Pharmacol; 2006 May; 57(5):685-92. PubMed ID: 16133532
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.
Ye L; Yang X; Guo E; Chen W; Lu L; Wang Y; Peng X; Yan T; Zhou F; Liu Z
PLoS One; 2014; 9(5):e96664. PubMed ID: 24797816
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.
Edginton AN; Zimmerman EI; Vasilyeva A; Baker SD; Panetta JC
Cancer Chemother Pharmacol; 2016 May; 77(5):1039-52. PubMed ID: 27053087
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
Mir O; Coriat R; Blanchet B; Durand JP; Boudou-Rouquette P; Michels J; Ropert S; Vidal M; Pol S; Chaussade S; Goldwasser F
PLoS One; 2012; 7(5):e37563. PubMed ID: 22666367
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.
Jiao Z; Ding JJ; Shen J; Liang HQ; Zhong LJ; Wang Y; Zhong MK; Lu WY
Br J Clin Pharmacol; 2008 Jun; 65(6):893-907. PubMed ID: 18279479
[TBL] [Abstract][Full Text] [Related]
11. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P; Narjoz C; Golmard JL; Thomas-Schoemann A; Mir O; Taieb F; Durand JP; Coriat R; Dauphin A; Vidal M; Tod M; Loriot MA; Goldwasser F; Blanchet B
PLoS One; 2012; 7(8):e42875. PubMed ID: 22912756
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Brendel E; Ludwig M; Lathia C; Robert C; Ropert S; Soria JC; Armand JP
Cancer Chemother Pharmacol; 2011 Jul; 68(1):53-61. PubMed ID: 20821331
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Miller AA; Murry DJ; Owzar K; Hollis DR; Kennedy EB; Abou-Alfa G; Desai A; Hwang J; Villalona-Calero MA; Dees EC; Lewis LD; Fakih MG; Edelman MJ; Millard F; Frank RC; Hohl RJ; Ratain MJ
J Clin Oncol; 2009 Apr; 27(11):1800-5. PubMed ID: 19255312
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
15. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
Shinsako K; Mizuno T; Terada T; Watanabe J; Kamba T; Nakamura E; Ogawa O; Inui K
Int J Clin Oncol; 2010 Oct; 15(5):512-4. PubMed ID: 20340037
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake.
Keunecke A; Hoefman S; Drenth HJ; Zisowsky J; Cleton A; Ploeger BA
Br J Clin Pharmacol; 2020 Dec; 86(12):2362-2376. PubMed ID: 32358822
[TBL] [Abstract][Full Text] [Related]
18. Saturable absorption of sorafenib in patients with solid tumors: a population model.
Hornecker M; Blanchet B; Billemont B; Sassi H; Ropert S; Taieb F; Mir O; Abbas H; Harcouet L; Coriat R; Dauphin A; Goldwasser F; Tod M
Invest New Drugs; 2012 Oct; 30(5):1991-2000. PubMed ID: 22006162
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
